Please assess the completion status of the following clinical trial:

Trial Title: Effects of Aqualief® in Patients With Xerostomia as Consequence of Radiotherapy for Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female which are 18 years of age or older~* Patients willing and able to give signed informed consent and, in the opinion of the Investigator, to comply with the protocol tests and procedures~* Subjects presenting:hyposalivation of grade 2 or greater (according to CTCAE scale vers. 4) and an objective, unstimulated salivary flow between 0.1 and 0.25 ml/min following radiation or radiation + systemic therapies with curative intent (definitive or postoperative), for tumors located in the head / neck region, completed from at least 6 months and free from cancer disease~* Absence of infections in the oral cavity~* Absence of antibiotics and antifungal treatments or any odontoiatric procedure in the 10 days before each treatment phase of the study.~Exclusion Criteria:~* Contraindications in administration of carnosine and hibiscus~* Known hypersensitivity to the components present in the product.~* Subjects taking products or medications to reduce symptoms of salivary gland hypofunction (Pilocarpine etc.)~* Patients with other underlying conditions that can cause xerostomia.~* Use of experimental drugs within 30 days prior to enrollment or during the study.~* Presence of clinical conditions that may interfere with the study evaluations.~* Pregnant or lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aqualief® tablets (Type: EXPERIMENTAL): oral mucoadesive tablets
- Placebo tablets (Type: PLACEBO_COMPARATOR): oral mucoadesive tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).